Summary
This content was automatically synthesized by Credo's AI models directly from the original source text.
AI summaries can make mistakes — double-check important details against the original source.
1 Sample Definition And Size
This paper is a commentary, not an original empirical study. It does not involve a defined sample or sample size; rather, it discusses existing evidence and trials regarding homocysteine, B vitamins, and dementia.
2 Study Type
Commentary (debate/opinion piece) responding to the omission of raised plasma homocysteine as a risk factor in the Lancet Commission report.
3 Conflicts Of Interest
JWM and AMcC are members of the American Society for Nutrition and the Alzheimer’s Prevention Expert Group of the Food for the Brain Foundation; BH has received speaker honoraria from the American Academy of Neurology and Warwar Pharma; HR and ADS are named inventors on a University of Oxford patent concerning use of B vitamins to prevent brain atrophy in mild cognitive impairment; ADS is also a member of the Scientific Advisory Boards of the Food for the Brain Foundation and Elysium Health, and a member of the Alzheimer’s Prevention Expert Group of the Food for the Brain Foundation ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/40551597/?utm_source=openai)).
4 Results Summary
The commentary highlights that elevated plasma total homocysteine is a modifiable risk factor for cognitive decline, dementia, and Alzheimer’s disease, supported by prior consensus statements and intervention trials showing that B vitamin–mediated homocysteine lowering slows brain atrophy and cognitive decline ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12284325/?utm_source=openai)). It cites the VITACOG trial, where B vitamin treatment reduced homocysteine by ~30%, with cognitive and clinical benefits observed in participants with baseline homocysteine above the median; regional brain atrophy in Alzheimer’s-affected areas was reduced more than sevenfold ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12284325/?utm_source=openai)). It also notes observational evidence, including a UK Biobank study of 192,214 participants showing protective effects of dietary intake of methionine, folate, B6, and B12 against Alzheimer’s (hazard ratios 0.30–0.77 for top vs bottom quartile), and a Swedish cohort (n=2,570) where high blood methionine was associated with 46% lower dementia risk and high homocysteine with 60% greater risk; high methionine-to-homocysteine ratio correlated with slower brain atrophy ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12284325/?utm_source=openai)).